FOXA1 expression in Iraqi women with ER+ breast cancer
Keywords:breast cancer, ER, FOXA1, immunohistochemistry, RT-qPCR
Background: Breast cancer (BC) is a heterogeneous disease that can be classified into many subtypes according to histopathological and molecular characteristics. Forkhead box protein A1 (FOXA1) is a transcriptional pioneer factor that opens chromatin allowing estrogen receptor (α-ER) access to its genomic targets. FOXA1 expression is related to luminal BC with a good prognosis.
Objectives: The present study is sought to determine the FOXA1 expression in Iraqi women with ER+ BC.
Methods: Forty-eight fresh malignant breast tissues were analyzed by immunohistochemistry assay to choose ER+ samples, and then by RT-qPCR to evaluate FOXA1 gene expression.
Results: The ER-positive samples were (72.91%) of the total samples, and the molecular subtype of luminal A was the most common with a percentage of 56.25%. It was also noted that the high expression of the FOXA1 gene is highly significant (p<0.05) in Iraqi women with BC when compared with healthy controls.
Conclusions: Highly significant FOXA1 expression was found in Iraqi women with BC makes it eligible to be a good predictor or a biomarker for BC.
Alwan, N.A.S.; Tawfeeq, F. and Mallah. N.A.G.(2019). Demographic and clinical profiles of female patients diagnosed with breast cancer in Iraq. J Contemp Med Sci. 5 ( 1) 14–19.
Anita Mangia et al. “Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?” Cancers (Basel) 11(9) (2019), pp. 1393–1393. DOI: 10.3390/cancers11091393. DOI: https://doi.org/10.3390/cancers11091393
Antoni Hurtado et al. “FOXA1 is a key determinant of estrogen receptor function and endocrine response”. Nat Genet 43(1) (2011), pp. 27–33. DOI: 10.1038/ng.730. DOI: https://doi.org/10.1038/ng.730
Azizun-Nisa et al. “Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer”. Asian Pac J Cancer Prev 9(4) (2008), pp. 553–556.
Bing Song et al. “Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression”. J Clin Invest 129(2) (2018), pp. 569–582. DOI: 10.1172/jci122367. DOI: https://doi.org/10.1172/JCI122367
Derek F. Amanatullah et al. “Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells”. Breast Cancer Res 19(1) (2017), pp. 121–121. DOI: 10.1186/s13058-017-0910-x. DOI: https://doi.org/10.1186/s13058-017-0910-x
Esther Rheinbay et al. “Recurrent and functional regulatory mutations in breast cancer”. Nature 547(7661) (2017), pp. 55–60. DOI: 10.1038/nature22992. DOI: https://doi.org/10.1038/nature22992
G Jiang et al. “Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function”. Theranostics 9(22) (2019), pp. 6501–6516. DOI: 10.7150/thno.34874. DOI: https://doi.org/10.7150/thno.34874
G M Clark, C K Osborne, and W L McGuire. “Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.” J Clin Oncol 2(10) (1984), pp. 1102–1109. DOI: 10.1200/jco.1922.214.171.1242. DOI: https://doi.org/10.1200/JCO.19126.96.36.1992
Gina M. Bernardo and Ruth A. Keri. “FOXA1: a transcription factor with parallel functions in development and cancer”. Biosci Rep 32(2) (2012), pp. 113–130. DOI: 10.1042/bsr20110046. DOI: https://doi.org/10.1042/BSR20110046
Huiyan Ma et al. “Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis”. Breast Cancer Res 20(1) (2018), pp. 5–6. DOI: 10.1186/s13058-017-0931-5. DOI: https://doi.org/10.1186/s13058-017-0931-5
J Laganière et al. “From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response”. Proc Natl Acad Sci U S A 102 (2005), pp. 11651–11656. DOI: 10.1073/pnas.0505575102. DOI: https://doi.org/10.1073/pnas.0505575102
J Rosai. Rosai and Ackerman’s Surgical Pathology. Ed. by and others. 10th. Vol. 1. Elsevier Inc. Italy, 2011.
J Xu et al. “Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER -2 and Ki-67”. Onco Targets Ther 11 (2018), pp. 2269–2275. DOI: https://doi.org/10.2147/OTT.S159830
Jason S. Carroll et al. “Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1”. Cell 122(1) (2005), pp. 33–43. DOI: 10.1016/j.cell.2005.05.008. DOI: https://doi.org/10.1016/j.cell.2005.05.008
Jiafeng Shou et al. “Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysis”. Breast 27 (2016), pp. 35–43. DOI: 10.1016/j.breast.2016.02.009. DOI: https://doi.org/10.1016/j.breast.2016.02.009
Jonathan G Moggs and George Orphanides. “Estrogen receptors: orchestrators of pleiotropic cellular responses”. EMBO Rep 2(9) (2001), pp. 775–781. DOI: 10.1093/embo-reports/kve185. DOI: https://doi.org/10.1093/embo-reports/kve185
Jonna Frasor et al. “Profiling of Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell Phenotype”. Endocrinology 144(10) (2003), pp. 4562–4574. DOI: 10.1210/en.2003-0567. DOI: https://doi.org/10.1210/en.2003-0567
Jumaah, Sh. S. (2013). Molecular Detection of Mutations in BRCA1, BRCA2, K-Ras and PIK3CA Genes in Iraqi Breast Cancer Patients and Their Families. Ph.D. thesis. Baghdad University. Iraq. Baghdad. pp.142.
K Michailidou. “Association analysis identifies 65 new breast cancer risk loci”. Nature 551(7678) (2018), pp. 92–94. DOI: 10.1038/nature24284. DOI: https://doi.org/10.1038/nature24284
K Wang et al. “Clinical significance and prognostic value of Forkhead box A1 expression in human epithelial ovarian cancer”. Oncol Lett 15 (2018), pp. 4457–4462. DOI: 10.3892/ol.2018.7899. DOI: https://doi.org/10.3892/ol.2018.7899
KELI HE et al. “Clinicopathological significance of forkhead box protein A1 in breast cancer: A meta-analysis”. Exper Ther Med 11(6) (2016), pp. 2525–2530. DOI: 10.3892/etm.2016.3229. DOI: https://doi.org/10.3892/etm.2016.3229
L A Cirillo et al. “Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome”. EMBO J 17(1) (1998), pp. 244–254. DOI: 10.1093/emboj/17.1.244. DOI: https://doi.org/10.1093/emboj/17.1.244
L Lin et al. “The hepatocyte nuclear factor 3 α gene, HNF3α (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas”. Cancer Res 62(18) (2002), pp. 5273–5279.
LakminiK. B Mudduwa. “Quick score of hormone receptor status of breast carcinoma: Correlation with the other clinicopathological prognostic parameters”. Indian J Pathol Microbiol 52(2) (2009), pp. 159–159. DOI: 10.4103/0377-4929.48906. DOI: https://doi.org/10.4103/0377-4929.48906
Luka Bolha et al. “Comparison of methods for relative quantification of gene expression using real-time PCR”. Acta Agric Slov 100(2) (2012), pp. 97–106. DOI: 10.2478/v10014-012-0018-z. DOI: https://doi.org/10.2478/v10014-012-0018-z
M. A. Climent et al. “Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment”. Breast 10(1) (2001), pp. 67–77. DOI: 10.1054/brst.2000.0225. DOI: https://doi.org/10.1054/brst.2000.0225
Marjolein Droog et al. “Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas”. Cancer Res 76(13) (2016), pp. 3773–3784. DOI: 10.1158/0008-5472.can-14-1813. DOI: https://doi.org/10.1158/0008-5472.CAN-14-1813
Michael H Cho et al. “Folliculin mutations are not associated with severe COPD”. BMC Med Genet 9(1) (2008). DOI: 10.1186/1471-2350-9-120. DOI: https://doi.org/10.1186/1471-2350-9-120
N A Alwan, F N Tawfeeq, and N A Mallah. “Demographic and clinical profiles of female patients diagnosed with breast cancer in Iraq”. J Contemp Med Sci 5(1) (2019), pp. 14–19. DOI: https://doi.org/10.22317/jcms.v5i1.544
Nidal M Almasri and Mohammad Al Hamad. “Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan”. Breast Cancer Res 7(5) (2005), pp. 598–604. DOI: 10.1186/bcr1200. DOI: https://doi.org/10.1186/bcr1200
Runnak A Majid et al. “Breast cancer in Iraq is associated with a unimodally distributed predominance of luminal type B over luminal type A surrogates from young to old age”. BMC Womens Health 17(1) (2017), pp. 27–28. DOI: 10.1186/s12905-017-0376-0. DOI: https://doi.org/10.1186/s12905-017-0376-0
Rutika J. Mehta et al. “FOXA1 is an independent prognostic marker for ER-positive breast cancer”. Breast Cancer Res Treat 131(3) (2012), pp. 881–890. DOI: 10.1007/s10549-011-1482-6. DOI: https://doi.org/10.1007/s10549-011-1482-6
S De Lara et al. “The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period”. BMC Cancer 19(1) (2004), pp. 187–187. DOI: 10.1186/s12885-019-5373-2. DOI: https://doi.org/10.1186/s12885-019-5373-2
Sunil Badve et al. “FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival”. Clin Cancer Res 13(15) (2007), pp. 4415–4421. DOI: 10.1158/1078-0432.ccr-07-0122. DOI: https://doi.org/10.1158/1078-0432.CCR-07-0122
T. Sekiya et al. “Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA”. Genes Dev 23(7) (2009), pp. 804–809. DOI: 10.1101/gad.1775509. DOI: https://doi.org/10.1101/gad.1775509
W M T Al-Nuaimy, A H Ahmed, and H A A Al-Nuaimy. “Immunohistochemical Evaluation of Triple Markers (ER, PR and HER-2/neu) in Carcinoma of the Breast in the North of Iraq”. Don J Med Lab Diagn 1(1) (2015), pp. 1–009.
X C Wu et al. “Cancer in North America, 1995-1999”. Cancer in North America III(NAACCR Combined Cancer Incidence Rates) (2002).
X Dai et al. “FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally Suppressing SOD2 and IL6”. Int J Biol Sci 15(5) (2019), pp. 1030–1041. DOI: https://doi.org/10.7150/ijbs.31009
X Wang et al. “Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer”. BioMed Res (2019). DOI: https://doi.org/10.1155/2019/7073498
Xiaoyong Fu et al. “FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer”. Proc Natl Acad Sci U S A 113 (2016), E6600–E6609. DOI: 10.1073/pnas.1612835113. DOI: https://doi.org/10.1073/pnas.1612835113
Y A Yang and J Yu. “Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer”. Genes Dis 2 (2015), pp. 144–151. DOI: 10.1016/j.gendis.2015.01.003. DOI: https://doi.org/10.1016/j.gendis.2015.01.003
Yuichi Hisamatsu et al. “Impact of FOXA1 Expression on the Prognosis of Patients with Hormone Receptor-Positive Breast Cancer”. Ann Surg Oncol 19(4) (2012), pp. 1145–1152. DOI: 10.1245/s10434-011-2094-4. DOI: https://doi.org/10.1245/s10434-011-2094-4
Yuichi Hisamatsu et al. “Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer”. Breast Cancer 22(5) (2015), pp. 520–528. DOI: 10.1007/s12282-013-0515-x. DOI: https://doi.org/10.1007/s12282-013-0515-x
Z Gu et al. “Clinical value of the changes of ER, PR, HER2 and Ki-67 expressions before and after neoadjuvant chemotherapy in breast cancer”. Open Sci J Clin Med 6(2) (2018), pp. 10–14.
How to Cite
Copyright (c) 2021 Iman H. Al-Bedairy, Mais Shamsa, Safaa aldeen Salim, Mohammed Mahdi, Karam Dawood, Abdul Hussein M. Al Faisal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain all proprietary rights, including copyright, such as patent and trade mark rights and rights to any process or procedure described in the article.